Ceftriaxone in prevention of complications after cesarean section and its influence on the newborn.
The study included 303 patients subjected to elective cesarean section. Thirty two (11%) patients were classified in group A (with prophylactic ceftriaxone administration), 28 (87.5%) of whom had uneventful postoperative courses and 4 (12.5%) who had complications. Group B (with therapeutical application of ceftriaxone) was composed of 135 (45%) patents, 127 (94.1%) with uneventful postoperative courses and 8 (5.9%) with complications. Group C (in whom other antibiotics were used) consisted of 95 (31%) patients, 72 (75.8%) with uneventful postoperative courses and 23 (24.2%) with complications. Group D (no antibiotics used) was composed of 41 (13%) patients, 31 (75.6%) with uneventful postoperative courses and 10 (24.4%) with complications. Statistical analysis revealed highly significant differences in distribution of complications according to whether any, and which one of the antibiotics was used (X2 = 17.81, p < 0.005). This difference mainly resulted from lower incidence of complications associated with ceftriaxone use than in patients with no antibiotic therapy (X2 = 11.66; p < 0.005) as well as in patients using other antibiotics (X2 = 15.95; p < 0.005). Significant difference was also noted when patients given antibiotics other than ceftriaxone were compared with patients receiving no antibiotics other than ceftriaxone were compared with patients receiving no antibiotic therapy (X2 = 4.45; p < 0.05). Group A of newborns included 17 (89.5%) with high Apgar score, while 2 children (10.5%) had the score below 8. Group B had 2 children (11.7%) with Apgar score below 8, while 15 (88.3%) children had higher scores.(ABSTRACT TRUNCATED AT 250 WORDS)
Clinic of Obstetrics and Gynecology, University Clinical Center, Belgrade.
V
V
Sulovic
A
A
Ljubic
M
M
Cvetkovic
O
O
Antonovic
M
M
Pervulov
D000328:Adult; D001424:Bacterial Infections / Q000517:prevention & control*; D002443:Ceftriaxone / Q000009:adverse effects / Q000627:therapeutic use*; D002585:Cesarean Section; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011183:Postoperative Complications / Q000517:prevention & control*; D011247:Pregnancy; D011292:Premedication; D016896:Treatment Outcome
D002443:Ceftriaxone